Yahoo · Oct 24, 2026
Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere
As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
NASDAQ · BLCO
Bausch + Lomb Corporation
Healthcare · Medical - Instruments & Supplies
$20.00
Down-$0.41 (-1.98%)
Updated Oct 31, 2026, 8:21 PM
SID Score
6.2/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 6.12B
- P/E ratio
- -20.07
- Dividend yield
- 0.00%
- 52-week range
- $14.44 – $21.36
- Volume
- 1.43M
- Avg. volume
- 492.22K
Price performance · BLCO
BLCO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BLCO closed at $20.00 after 21 trading sessions, up 16.89% for the selected period.
- Last close
- $20.00
- Period change
- +16.89%
- Period low
- $15.81
- Period high
- $20.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $20.85 | $20.85 | $19.83 | $20.00 | 1.43M |
| Oct 29, 2026 | $20.885 | $21.36 | $20.27 | $20.40 | 3.45M |
| Oct 28, 2026 | $18.54 | $20.43 | $18.46 | $20.40 | 4.11M |
| Oct 27, 2026 | $17.43 | $17.76 | $17.32 | $17.62 | 450.8K |
| Oct 26, 2026 | $17.41 | $17.755 | $17.30 | $17.58 | 499.28K |
| Oct 23, 2026 | $17.26 | $17.50 | $17.11 | $17.47 | 412.13K |
| Oct 22, 2026 | $17.12 | $17.45 | $17.007 | $17.43 | 426.37K |
| Oct 21, 2026 | $16.89 | $17.24 | $16.68 | $17.18 | 450.78K |
| Oct 20, 2026 | $16.80 | $17.05 | $16.67 | $16.93 | 502.44K |
| Oct 19, 2026 | $16.30 | $16.77 | $16.30 | $16.61 | 357.03K |
| Oct 16, 2026 | $16.75 | $16.81 | $16.251 | $16.49 | 419.85K |
| Oct 15, 2026 | $16.18 | $16.72 | $16.09 | $16.66 | 898.89K |
| Oct 14, 2026 | $15.73 | $16.21 | $15.70 | $16.04 | 486.31K |
| Oct 13, 2026 | $16.14 | $16.42 | $15.70 | $15.81 | 757.5K |
| Oct 12, 2026 | $16.83 | $16.845 | $15.47 | $16.07 | 3.01M |
| Oct 9, 2026 | $17.21 | $17.47 | $17.19 | $17.30 | 234.32K |
| Oct 8, 2026 | $17.50 | $17.50 | $17.06 | $17.15 | 358.67K |
| Oct 7, 2026 | $17.43 | $17.44 | $17.21 | $17.34 | 349.05K |
| Oct 6, 2026 | $17.14 | $17.31 | $16.9501 | $17.18 | 319.7K |
| Oct 5, 2026 | $17.16 | $17.415 | $17.075 | $17.17 | 402.8K |
| Oct 2, 2026 | $17.13 | $17.16 | $16.80 | $17.11 | 354.1K |
Latest BLCO news
The latest Smart Investors Daily articles mentioning BLCO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BLCO research
Overview
Company profile and research snapshot.
Company profile
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $18.00
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | JP Morgan | Neutral | — |
| Oct 29, 2026 | RBC Capital | Outperform | — |
| Oct 29, 2026 | Citigroup | Buy | — |
| Oct 29, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 7, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up
Dan Loeb‘s Third Point opened a position in Bausch + Lomb Corp. in the second quarter, buying around 85,000 shares, valued at about $1.4 million, as of June 30. Recent News: On Oct. 12, Bausch + Lomb announced that Thomas...
Yahoo · Oct 16, 2026
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
Bausch + Lomb currently trades at $16.69 per share and has shown little upside over the past six months, posting a middling return of 0.6%. The stock also fell short of the S&P 500’s 9.7% gain during that period.
Benzinga · Oct 12, 2026
Why Is Bausch + Lomb Stock Falling Monday?
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
